SLC39A6/ZIP6: a Key Member of Zinc Transporters, a Novel Targeting Antigen of ADC!
SLC39A6 (also known as ZIP6 or LIV-1) is a member of the SLC39A/ZIP zinc transporter protein family. The primary function of SLC39A6 is to transfer zinc from the extracellular to the cytoplasm or from the organelle to the cytoplasm. Thus, SLC39A6 plays indispensable roles in maintaining zinc homeostasis by regulating the influx of zinc. Importantly, accumulating studies are suggesting that SLC39A6 is highly expressed in a variety of tumor cells but limited expression in normal tissues, making it an attractive candidate for ADC therapy!
Earlier, pharmaceutical giant Merck has struck a deal to develop Seagen’ Phase II ADC (ladiratuzumab vedotin, also named MK-6440 or SGN-LIV1A). Merck paid $1.6 billion to co-develop and co-commercialize ladiratuzumab vedotin. SGN-LIV1A is a novel ADC, targeting the zinc transporter SLC39A6 for the treatment of solid tumors. Importantly, accumulating studies are suggesting that SLC39A6 is highly expressed in a variety of tumor cells but limited expression in normal tissues, making it an attractive candidate for ADC therapy! (Read more about SLC39A6)
To fully support researchers and pharmaceutical companies in their research on SLC39A6 in tumors such as esophageal and breast cancers, CUSABIO presents the SLC39A6 active protein product (Code: CSB-BP621669HU1) to assist you in your research on the mechanism of SLC39A6 or its potential clinical value.
|
Recombinant Human SLC39A6, partial (Active) (CSB-BP621669HU1)
|
